Please assess the completion status of the following clinical trial:

Trial Title: Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of schizophrenia according to DSM-IV TR criteria.~2. Postmenopausal patients. Post-menopausal is defined as 1) aged over 45 years with at least one year of amenorrhea and levels of FSH over 20 UI/L or 2) aged over 50 years with at least one year of amenorrhea.~3. Patients who have been taking a stable dose of antispsychotic medication for at least the 30 days before the start of the study.~4. The presence of significant negative symptoms (defined as one or more negative symptoms with a severity of over 4 on the PANSS scale).~5. General written informed consent by patients or their legal representative.~6. For the genotypic study, a specific informed consent signed by the patients or legal representative is required.~Exclusion criteria:~1. A diagnosis of substance abuse/dependence in the previous 6 months.~2. Mental retardation~3. A diagnosis of major depression (according to DSM-IV TR criteria).~4. Endocrine alterations related to sexual hormones, liver insufficiency including cholestasis, severe renal insufficiency.~5. History or current condition of thromboembolism, breast cancer, abnormal uterine bleeding or stroke.~6. Patients in hormone replacement therapy.~7. Known allergy or hypersensitivity to the active ingredient of the investigational drug, or to any of its excipients or lactose.~8. To be receiving treatment in another clinical trial.~9. To present any severe concomitant disease that in the researcher's opinion can compromise completion of the study or affect the patient's tolerance to this treatment.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raloxifene hydrochloride 60 mg (Type: EXPERIMENTAL): Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding.
- Lactosa (placebo) (Type: PLACEBO_COMPARATOR): Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete